The process transformation achieved outstanding results

As the dust of mergers settled, AstraZeneca emerged assessing the impact of its marketing and development plans on pharmacovigilance.  'Dramatic' was the conclusion.  In 2002, the Clinical Drug Safety team processed over 50,000 individual adverse event (AE) case reports globally.  Broadly harmonised, but with a lot of local variation, the system funnelled reports worldwide from seven collecting sites in Europe and the USA to a central database.  It worked.  However, continuing growth in the products and drugs portfolio would take the annual case report figure well past the 10,000 mark by 2007.  Growing a quality workforce to match was currently a fanciful notion.  AstraZeneca's Clinical Drug Safety team decided they must re-engineer their case handling process to achieve the vast productivity increase approaching, whilst maintaining the highest quality.

To read the case study in full, please click on the pdf link below:

Pharmacovigilance for the Future.pdf